Form 4: Director Acquires Stock Options at Achieve Life Sciences

Director Christopher Martin acquired 47,250 stock options with an exercise price of $5.59, vesting over 36 months starting May 11, 2026.

Summary

• Christopher Martin, a Director at Achieve Life Sciences, Inc., acquired 47,250 stock options.
• The stock options have an exercise price of $5.59 per share.
• These options are set to vest in substantially equal monthly installments over 36 months, commencing on May 11, 2026.
• Vesting is contingent upon Mr. Martin's continued service to the Issuer on each vesting date.
• The earliest transaction date reported is May 11, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director, which is typical compensation and not indicative of immediate positive or negative company performance.

Positives

• Director's acquisition of stock options indicates a commitment to the company's future performance.
• The vesting schedule over 36 months aligns the director's incentives with long-term value creation.

Risks

• The value of the stock options is subject to the future performance of Achieve Life Sciences' stock price.
• Vesting is contingent on continued service, meaning any departure before vesting completion would result in forfeiture of unvested options.

Future Outlook

The stock options are exercisable until May 11, 2036, with vesting commencing on May 11, 2026, over a 36-month period.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology and life sciences sector, often used as a long-term incentive to align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The issuance of stock options dilutes existing ownership slightly, but the vesting schedule aims to incentivize long-term performance, potentially benefiting shareholders if the stock price increases.

Next Steps

• Christopher Martin will receive monthly installments of stock options over 36 months, starting May 11, 2026, provided he remains in service to the Issuer.

Key Dates

Keywords

Form 4, SEC Filing, Stock Options, Achieve Life Sciences, ACHV, Director, Beneficial Ownership, Vesting Schedule